N C Te Grootenhuis1, A G J van der Zee1, H C van Doorn2, J van der Velden3, I Vergote4, V Zanagnolo5, P J Baldwin6, K N Gaarenstroom7, E B van Dorst8, J W Trum9, B F M Slangen10, I B Runnebaum11, K Tamussino12, R H Hermans13, D M Provencher14, G H de Bock15, J A de Hullu16, M H M Oonk17. 1. Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. 2. Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands. 3. Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, Netherlands. 4. Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium. 5. Department of Obstetrics and Gynaecology, European Cancer Institute, Milan, Italy. 6. Department of Gynaecological Oncology, Addenbrooke's Hospital, Cambridge, United Kingdom. 7. Department of Obstetrics and Gynaecology, Leiden University Medical Center, Leiden, Netherlands. 8. Department of Obstetrics and Gynaecology, University Medical Center Utrecht, Utrecht, Netherlands. 9. Department of Obstetrics and Gynaecology, VU Medical Center, Amsterdam, Netherlands. 10. Department of Obstetrics and Gynaecology, Maastricht University Medical Center, Maastricht, Netherlands. 11. Department of Obstetrics and Gynaecology, University Hospital Jena, Jena, Germany. 12. Department of Obstetrics and Gynaecology, Medical University Graz, Graz, Austria. 13. Department of Obstetrics and Gynaecology, Catharina Hospital, Eindhoven, Netherlands. 14. Department of Obstetrics and Gynaecology, Centre Hospitalier de l'Université de Montréal, Montreal, Canada. 15. Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. 16. Department of Obstetrics and Gynaecology, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands. 17. Department of Obstetrics and Gynaecology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Electronic address: m.h.m.oonk@umcg.nl.
Abstract
OBJECTIVE: In 2008 GROINSS-V-I, the largest validation trial on the sentinel node (SN) procedure in vulvar cancer, showed that application of the SN-procedure in patients with early-stage vulvar cancer is safe. The current study aimed to evaluate long-term follow-up of these patients regarding recurrences and survival. METHODS: From 2000 until 2006 GROINSS-V-I included 377 patients with unifocal squamous cell carcinoma of the vulva (T1, <4 cm), who underwent the SN-procedure. Only in case of SN metastases an inguinofemoral lymphadenectomy was performed. For the present study follow-up was completed until March 2015. RESULTS: Themedian follow-up was 105 months (range 0–179). The overall local recurrence ratewas 27.2% at 5 years and 39.5% at 10 years after primary treatment, while for SN-negative patients 24.6% and 36.4%, and for SN-positive patients 33.2% and 46.4% respectively (p = 0.03). In 39/253 SN-negative patients (15.4%) an inguinofemoral lymphadenectomy was performed, because of a local recurrence. Isolated groin recurrence rate was 2.5% for SN-negative patients and 8.0% for SN-positive patients at 5 years. Disease-specific 10-year survival was 91% for SN-negative patients compared to 65% for SN-positive patients (p b .0001). For all patients, 10-year disease-specific survival decreased from 90% for patients without to 69% for patients with a local recurrence (p b .0001).
OBJECTIVE: In 2008 GROINSS-V-I, the largest validation trial on the sentinel node (SN) procedure in vulvar cancer, showed that application of the SN-procedure in patients with early-stage vulvar cancer is safe. The current study aimed to evaluate long-term follow-up of these patients regarding recurrences and survival. METHODS: From 2000 until 2006 GROINSS-V-I included 377 patients with unifocal squamous cell carcinoma of the vulva (T1, <4 cm), who underwent the SN-procedure. Only in case of SN metastases an inguinofemoral lymphadenectomy was performed. For the present study follow-up was completed until March 2015. RESULTS: Themedian follow-up was 105 months (range 0–179). The overall local recurrence ratewas 27.2% at 5 years and 39.5% at 10 years after primary treatment, while for SN-negative patients 24.6% and 36.4%, and for SN-positive patients 33.2% and 46.4% respectively (p = 0.03). In 39/253 SN-negative patients (15.4%) an inguinofemoral lymphadenectomy was performed, because of a local recurrence. Isolated groin recurrence rate was 2.5% for SN-negative patients and 8.0% for SN-positive patients at 5 years. Disease-specific 10-year survival was 91% for SN-negative patients compared to 65% for SN-positive patients (p b .0001). For all patients, 10-year disease-specific survival decreased from 90% for patients without to 69% for patients with a local recurrence (p b .0001).
Entities:
Keywords:
Long-term follow-up; Sentinel node; Vulvar cancer
Authors: Stephanie Cham; Ling Chen; William M Burke; June Y Hou; Ana I Tergas; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright Journal: Obstet Gynecol Date: 2016-10 Impact factor: 7.661
Authors: Vance Broach; Nadeem R Abu-Rustum; Yukio Sonoda; Carol L Brown; Elizabeth Jewell; Ginger Gardner; Dennis S Chi; Oliver Zivanovic; Mario M Leitao Journal: Int J Gynecol Cancer Date: 2020-02-18 Impact factor: 3.437
Authors: Angiolo Gadducci; Sabina Pistolesi; Stefania Cosio; Chiara Comunale; Antonio Fanucchi; Antonio Giuseppe Naccarato Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155
Authors: Franziska Siegenthaler; Sara Imboden; Laura Knabben; Stefan Mohr; Andrea Papadia; Michael D Mueller Journal: Front Oncol Date: 2021-04-22 Impact factor: 6.244